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INTRODUCTION
A human Japanese encephalitis (JE) case is considered to have elevated temperature (over 38 o C) along with altered consciousness or unconsciousness. For confirmation of a case as JE, it needs to be serologically examined and found postive for specific anti-JE IgM in the cerebro spinal fluid or serum at the time of illenss.
Treatment and Management
• No specific treatment is available. Supportive and symptomatic treatment in indicated.
• Meticulous nuring care is most important.
• If the patient is unconscious, a Ryle's tube needs to be introduced.
• I.V. fluids shold be avoided.
• Avoid indwelling catheter in conscious patient.
• Dextrose solution only to be considered if there is dehydration.
• In case of raised cranial pressure, 20% Mannitol injection to be given 8 hourly for 48 hours. (Pediatric dose: 1.5 gm./ Kg. can be given 8 hourly).
• Antibiotics to be used only if the patient is having secondary infection.
• Corticosteroids should be avoided unless indicated.
• (Figures 10 and 11) 
LABORATORY CONFIRMATION OF JE
There are four designated referral laboratories, namely National Public Health Laboratory (Teku), Vector Borne Diseases Research and Training Center (Hetauda), B.P. Koirala Institute of Medical Sciences (Dharan) and JE Laboratory (Nepalgunj), for confirmatory diagnosis of JE. (Table I ) Generally paired serum or CSF samples are collected for the confirmatory diagnosis using anti-JE-IgM capture ELISA.
Internal quality control is done at National Public Health Laboratory (Teku), whereas external quality assurance is performed at Armed Force Research Institute of Medical Sciences, Thailand. From 1999 to 2003, with the support of the USAID funded EHPProject in Nepal on infectious diseases, the laboratory capacities of above-mentioned laboratories were upgraded. It established a JE diagnostic laboratory at Bheri zonal hospital premises. The project also helped in transporting the samples to referral laboratories from the periphery. Now, this responsibility has been taken over by World Health Organization (Polio Eradication Nepal). 
CONTROL MEASURES
Control measures during inter epidemic period of JE
Vaccination for JE prevention and control
Intermittent vaccination against JE in selected districts 225,000 doses of live attenuated SA-14-14-2 JE vaccine (Tabel II) were received in donation form Boran pharmaceuticals, South Korea for the first time in Nepal. Altogether 224,000 children aged between 1 to 15 years were vaccinated in Banke, Bardiya and Kailali districts during 1999. From China, 2,000,000 doses of inactivated vaccine (Table III) 
Types of human vaccines  Mouse brain inactivated vaccine:
It is Nagayama strain (Beijing-1 strain) vaccine. Two doses of this vaccine are given subcutaneously 4 weeks apart. Booster dose is given after 1 year and subsequent booster doses are given at every 3 years. Dose is 0.5 ml. for 1-3 year's age group and 1 ml. for above 3 years age group.  Cell culture inactivated vaccine: It is Beijing P-3 strain vaccine and propagated in primary hamster kidney cells. Two doses of this vaccine are given subcutaneously 1 week apart. Booster doses are given after 6 months to 1 year and 3 years later. Dose is 0.5 ml. for all age groups.
Types of animal vaccines:
WHO does not recommend vaccination of swine population as : It is used in pigs to prevent stillbirth. Dose is 1 ml. and given intramuscularly. For sows, the booster dose is given in the following year. For piglets and gilts, 2 doses of vaccines are applied 3 to 4 weeks apart and booster dose is given at the age of 1 year.
• Ministry of Agriculture, Department of livestock services has vaccinated around 200,000 pigs against JE in terai zone during February 2001.
• Cell culture live attenuated vaccine: It is SA-14-14-2 strain vaccine and propagated in primary hamster kidney cells. Single dose of vaccine is given subcutaneously. Booster dose is given after 2 years. Dose is 0.5 ml. for all age groups.
